Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant
pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab
with platinum doublet chemotherapy (3 cycles) followed by surgery for participants with Stage
IA3, IB and IIA non-small-cell lung cancer (NSCLC). Participants will be offered
pembrolizumab (6 cycles), and standard of care adjuvant chemotherapy (4 cycles) if
applicable.
Phase:
Phase 2
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre